Login / Signup
Li Wang
ORCID
Publication Activity (10 Years)
Years Active: 2022-2022
Publications (10 Years): 5
Top Topics
Drug Delivery
Tyrosine Kinase
Cancer Therapy
Big Data
Top Venues
British journal of pharmacology
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Huanyu Ding
,
Minchun Jiang
,
Chi Wai Lau
,
JianFang Luo
,
Andrew Man Lok Chan
,
Li Wang
,
Yu Huang
Curaxin CBL0137 inhibits endothelial inflammation and atherogenesis via suppression of Src-YAP signaling axis.
British journal of pharmacology
(2022)
Huanyu Ding
,
Minchun Jiang
,
Chi Wai Lau
,
JianFang Luo
,
Andrew Man Lok Chan
,
Li Wang
,
Yu Huang
Curaxin CBL0137 inhibits endothelial inflammation and atherogenesis via suppression of the Src-YAP signalling axis.
British journal of pharmacology
(2022)
Huanyu Ding
,
Minchun Jiang
,
Chi Wai Lau
,
JianFang Luo
,
Andrew Man Lok Chan
,
Li Wang
,
Yu Huang
Curaxin CBL0137 inhibits endothelial inflammation and atherogenesis via suppression of the Src-YAP signalling axis.
British journal of pharmacology
180 (8) (2022)
Huanyu Ding
,
Minchun Jiang
,
Chi Wai Lau
,
JianFang Luo
,
Andrew Man Lok Chan
,
Li Wang
,
Yu Huang
Curaxin CBL0137 inhibits endothelial inflammation and atherogenesis via suppression of the Src-YAP signalling axis.
British journal of pharmacology
180 (8) (2022)
Huanyu Ding
,
Minchun Jiang
,
Chi Wai Lau
,
JianFang Luo
,
Andrew Man Lok Chan
,
Li Wang
,
Yu Huang
Curaxin CBL0137 inhibits endothelial inflammation and atherogenesis via suppression of the Src-YAP signalling axis.
British journal of pharmacology
180 (8) (2022)